Literature DB >> 26952812

Glioblastoma: Radiation treatment margins, how small is large enough?

A Gabriella Wernicke1, Andrew W Smith2, Shoshana Taube3, Minesh P Mehta4.   

Abstract

Standard treatment for glioblastoma consists of surgical resection followed by radiation therapy with concurrent and adjuvant chemotherapy. Conventional radiation clinical treatment volumes include a 2- to 3-cm margin around magnetic resonance imaging or computed tomography enhancing abnormalities in the brain as well as a margin around the T2 or fluid-attenuated inversion recovery abnormality. However, there remains significant variability with respect to whether such extensive margins are necessary. Collectively, we as authors of this manuscript also use different margins, with A.G.W. employing European Organization for Research and Treatment of Cancer recommendations of a 2- to 3-cm margin on T1 enhancement for 60 Gy and M.P.M. using Radiation Therapy Oncology Group recommendations of 2 cm on T2 signal abnormality for the initial 46 Gy and 2.5-cm margin on T1 enhancement for a 14-Gy boost. Our experiences reflect the heterogeneity of margin definition and selection for this disease and underscore an important area of further research to minimize this variability. In this article, we review studies exploring recurrence patterns and outcomes in patients treated using both conventional and more limited margins. We conclude that treating to "smaller" margins does not alter recurrence patterns nor does it result in inferior survival, but whether this is because of the inherently limited benefit of radiation therapy in the first place, or whether it is truly because microscopic tumor control at larger distances is not an issue, remains unestablished.
Copyright © 2016 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26952812     DOI: 10.1016/j.prro.2015.12.002

Source DB:  PubMed          Journal:  Pract Radiat Oncol        ISSN: 1879-8500


  19 in total

Review 1.  Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

Authors:  Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

2.  NRG brain tumor specialists consensus guidelines for glioblastoma contouring.

Authors:  Tim J Kruser; Walter R Bosch; Shahed N Badiyan; Joseph A Bovi; Amol J Ghia; Michelle M Kim; Abhishek A Solanki; Sean Sachdev; Christina Tsien; Tony J C Wang; Minesh P Mehta; Kevin P McMullen
Journal:  J Neurooncol       Date:  2019-03-19       Impact factor: 4.130

Review 3.  Neural stem cells, the subventricular zone and radiotherapy: implications for treating glioblastoma.

Authors:  Andrew W Smith; Minesh P Mehta; A Gabriella Wernicke
Journal:  J Neurooncol       Date:  2016-04-23       Impact factor: 4.130

4.  Subventricular zone-associated glioblastoma: A call for translational research to guide clinical decision making.

Authors:  Andrew W Smith; Bhupesh Parashar; A Gabriella Wernicke
Journal:  Neurogenesis (Austin)       Date:  2016-08-19

5.  Radiation-Induced DNA Damage Cooperates with Heterozygosity of TP53 and PTEN to Generate High-Grade Gliomas.

Authors:  Pavlina K Todorova; Eliot Fletcher-Sananikone; Bipasha Mukherjee; Rahul Kollipara; Vamsidhara Vemireddy; Xian-Jin Xie; Peter M Guida; Michael D Story; Kimmo Hatanpaa; Amyn A Habib; Ralf Kittler; Robert Bachoo; Robert Hromas; John R Floyd; Sandeep Burma
Journal:  Cancer Res       Date:  2019-05-14       Impact factor: 12.701

6.  Location of subventricular zone recurrence and its radiation dose predicts survival in patients with glioblastoma.

Authors:  Brent D Weinberg; Lauren Boreta; Steve Braunstein; Soonmee Cha
Journal:  J Neurooncol       Date:  2018-03-15       Impact factor: 4.130

7.  Mechanisms of post-radiation injury: cerebral microinfarction not a significant factor.

Authors:  J A Molad; D T Blumenthal; F Bokstein; M Findler; I Finkel; N M Bornstein; S Yust-Katz; E Auriel
Journal:  J Neurooncol       Date:  2016-10-18       Impact factor: 4.130

8.  A Feasibility Study of Personalized Prescription Schemes for Glioblastoma Patients Using a Proliferation and Invasion Glioma Model.

Authors:  Minsun Kim; Jakob Kotas; Jason Rockhill; Mark Phillips
Journal:  Cancers (Basel)       Date:  2017-05-13       Impact factor: 6.639

Review 9.  Advances in Radiotherapy for Glioblastoma.

Authors:  Justin Mann; Rohan Ramakrishna; Rajiv Magge; A Gabriella Wernicke
Journal:  Front Neurol       Date:  2018-01-15       Impact factor: 4.003

10.  Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.

Authors:  J Biau; E Chautard; E De Schlichting; G Dupic; B Pereira; A Fogli; M Müller-Barthélémy; P Dalloz; T Khalil; A F Dillies; X Durando; C Godfraind; P Verrelle
Journal:  Radiat Oncol       Date:  2017-12-06       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.